Analytical Data
-
Gene name
TRIP6
- Application
-
Alternative Names
TRIP6；OIP1；Thyroid receptor-interacting Protein 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15654
-
Expression Region
1-476aa
-
AA Sequence
MSGPTWLPPK QPEPARAPQG RAIPRGTPGP PPAHGAALQP HPRVNFCPLP SEQCYQAPGG PEDRGPAWVG SHGVLQHTQG LPADRGGLRP GSLDAEIDLL SSTLAELNGG RGHASRRPDR QAYEPPPPPA YRTGSLKPNP ASPLPASPYG GPTPASYTTA STPAGPAFPV QVKVAQPVRG CGPPRRGASQ ASGPLPGPHF PLPGRGEVWG PGYRSQREPG PGAKEEAAGV SGPAGRGRGG EHGPQVPLSQ PPEDELDRLT KKLVHDMNHP PSGEYFGQCG GCGEDVVGDG AGVVALDRVF HVGCFVCSTC RAQLRGQHFY AVERRAYCEG CYVATLEKCA TCSQPILDRI LRAMGKAYHP GCFTCVVCHR GLDGIPFTVD ATSQIHCIED FHRKFAPRCS VCGGAIMPEP GQEETVRIVA LDRSFHIGCY KCEECGLLLS SEGECQGCYP LDGHILCKAC SAWRIQELSA TVTTDC
-
Molecular Weight
50.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRIP6 (thyroid hormone receptor interactor 6) is a member of the zyxin family of proteins and is known for its role in cytoskeletal organization and cell signaling. It acts as a focal adhesion protein, mediating interactions between the cytoskeleton and extracellular matrix, which is crucial for cell adhesion, migration, and tissue remodeling. The study of TRIP6 and its recombinant protein has gained significance in recent years due to its involvement in various cellular processes and potential implications in cancer metastasis and other diseases. Research has shown that TRIP6 can influence the pathophysiology of several conditions by regulating gene expression and protein interactions, particularly in response to extracellular signals. Understanding the structure and function of TRIP6 through recombinant protein studies can provide insights into its mechanisms of action and its potential as a therapeutic target. The ability to produce TRIP6 as a recombinant protein allows for extensive biochemical characterization, functional assays, and the exploration of its role in various signaling pathways. These studies are essential for developing targeted therapies that can modulate TRIP6 activity in disease contexts, thereby highlighting its potential as a biomarker and a target for novel treatments.
